Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists.

MLA

Goldenberg, Ronald M., et al. “Management of Type 2 Diabetes, Obesity, or Nonalcoholic Steatohepatitis with High‐dose GLP‐1 Receptor Agonists and GLP‐1 Receptor‐based Co‐agonists.” Obesity Reviews, vol. 25, no. 3, Mar. 2024, pp. 1–20. EBSCOhost, https://doi.org/10.1111/obr.13663.

APA

Goldenberg, R. M., Gilbert, J. D., Manjoo, P., Pedersen, S. D., Woo, V. C., & Lovshin, J. A. (2024). Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists. Obesity Reviews, 25(3), 1–20. https://doi.org/10.1111/obr.13663

Chicago

Goldenberg, Ronald M., Jeremy D. Gilbert, Priya Manjoo, Sue D. Pedersen, Vincent C. Woo, and Julie A. Lovshin. 2024. “Management of Type 2 Diabetes, Obesity, or Nonalcoholic Steatohepatitis with High‐dose GLP‐1 Receptor Agonists and GLP‐1 Receptor‐based Co‐agonists.” Obesity Reviews 25 (3): 1–20. doi:10.1111/obr.13663.